Center-Authored Papers

Filters: Author is Gulati, Roman  [Clear All Filters]
2008
Telesca D, Etzioni R, Gulati R.  2008.  Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.. Biometrics. 64(1):10-9. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF et al..  2008.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.. Cancer causes & control : CCC. 19(2):175-81. Abstract
Etzioni R, Gulati R, Falcon S, Penson DF.  2008.  Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.. Medical decision making : an international journal of the Society for Medical Decision Making. 28(3):323-31. Abstract
2009
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss NS, Kristal AR, Etzioni R.  2009.  Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(3):808-15. Abstract
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.  2009.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.. Journal of the National Cancer Institute. 101(6):374-83. Abstract
2010
Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T.  2010.  Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.. Anti-cancer drugs. 21(4):423-32. Abstract
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni R, Higano CS.  2010.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73. Abstract
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV.  2010.  Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos.. The American journal of clinical nutrition. 91(3):777-85. Abstract
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R.  2010.  Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.. Biostatistics (Oxford, England). 11(4):707-19. Abstract
2011
Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.  2011.  Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.. Journal of clinical epidemiology. 64(12):1412-7. Abstract
Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LYT, Katcher J, Lee S-Y, Heijnsdijk EAM, Draisma G, de Koning HJ et al..  2011.  What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(5):740-50. Abstract
2012
Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EAM, Katcher J, de Koning HJ, Etzioni R.  2012.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.. Cancer causes & control : CCC. 23(6):827-35. Abstract
Lewinshtein D, Gulati R, Nelson PS, Porter CR.  2012.  Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.. BJU international. 109(5):706-12. Abstract
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EAM, Katcher J, Draisma G, Feuer EJ, de Koning HJ et al..  2012.  The prostate cancer conundrum revisited : Treatment changes and prostate cancer mortality declines.. Cancer. Abstract
Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.  2012.  Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(15):1864-70. Abstract
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter BH, Etzioni R.  2012.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19):5471-5478. Abstract
2013
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT et al..  2013.  Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.. PloS one. 8(10):e78881. Abstract
Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B et al..  2013.  Single cell transcriptomic analysis of prostate cancer cells.. BMC molecular biology. 14:6. Abstract
Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.  2013.  Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.. Medical care. 51(4):295-300. Abstract
Etzioni R, Gulati R.  2013.  Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.. Medical care. 51(4):304-6. Abstract
Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R.  2013.  Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial.. Journal of the National Cancer Institute. Abstract
Gulati R, Gore JL, Etzioni R.  2013.  Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.. Annals of internal medicine. 158(3):145-53. Abstract
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR.  2013.  Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia? American journal of epidemiology. Abstract
Etzioni R, Gulati R, Mallinger L, Mandelblatt J.  2013.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.. Annals of internal medicine. 158(11):831-8. Abstract